A Multicenter Clinical Study of Echocardiographic Assessment of Right Heart Function and Implications of Prognosis in Diabetes

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35-79
SponsorXie Mingxing

About this trial

The aims of this study are to 1. Evaluate the right heart structure and function in T2DM and Prediabetes patients by speckle tracking echocardiography, and to further investigate the influence of left heart on right heart structure and function in T2DM and Prediabetes patients. 2. To explore the prognostic value of right ventricular function in T2DM patients.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

All patients with type 2 diabetes mellitus and prediabetes were diagnosed according to the WHO 2006 criteria, aged 35 -79 years, who are undergoing echocardiography examination in clinical needs.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,300 Participants
are grouped into 3 trial groups
Group A: type 2 diabetes
Group B: Prediabetes
Group C: normal glucose metabolism(NGM)

Trial outcomes

Primary outcomes

1

major adverse cardiovascular events

including myocardial infarction, cerebrovascular stroke, or cardiovascular death, hospitalization for heart failure

Time frame
through study completion, an average of 6 year

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xie Mingxing

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Sponsor institution

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborator

Shanghai Zhongshan Hospital

Collaborator

Henan Provincial People's Hospital

Collaborator

Wuhan Asia Heart Hospital

Collaborator

Guangdong Provincial People's Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: